FDA Finalises NDI Guidance: Flexible Safety Reviews, 25-Year Use Benchmark
The FDA has issued final guidance for New Dietary Ingredient (NDI) notifications, emphasising a flexible, case-by-case approach to safety data and identifying a 25-year benchmark for documented safe use. This clarifies submission requirements but retains practical implementation challenges for manufacturers.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Washington D.C., United States — 19 October 2026
The US Food and Drug Administration (FDA) has published its final guidance on New Dietary Ingredient (NDI) notifications, outlining the information required to demonstrate ingredient identity and safety for market introduction. The document signals a notable shift towards a more flexible, case-by-case evaluation framework, departing from earlier, more prescriptive drafts. It acknowledges alternative testing methodologies and updates recommendations for data on ingredient identity and safety.
A critical point within the guidance is the emphasis on a documented history of safe use, with the FDA suggesting a 25-year benchmark for establishing safety without extensive novel toxicity studies. This provides a clearer, albeit stringent, threshold for manufacturers leveraging historical data. Specific requirements for categories like botanicals and probiotics are also detailed, addressing the unique complexities associated with these ingredient types.
While the industry broadly welcomes the FDA's move towards increased flexibility and clarity, some concerns persist regarding the practical application of certain recommendations. Specifically, the definition and scope of 'documented history of safe use' beyond the 25-year mark, and the exact parameters for 'alternative testing methods', still require further granular interpretation. Manufacturers will need to invest in expert regulatory counsel to navigate these nuances effectively.
What this means for United States
US manufacturers and brand owners face immediate adjustments to their NDI submission strategies. Compliance departments must update internal protocols to reflect the 25-year safe use benchmark, which will expedite review for established ingredients but significantly increase data generation costs for novel ones. Reformulation windows may extend by 4-6 months for ingredients requiring additional safety studies to meet the new flexible criteria. Companies with robust historical use data can gain a competitive advantage through faster market entry, while others face increased R&D expenditure and potentially longer lead times to market for truly innovative ingredients. Maintaining regulatory agility is paramount to avoiding costly submission rejections.
The FDA's guidance aims to streamline the notification process, ultimately benefiting consumers by ensuring new ingredients meet safety standards before market entry. However, brand owners must now critically assess their ingredient portfolios against these updated benchmarks. Procurement leads should anticipate potential price increases from suppliers for novel ingredients due to the higher burden of proof required for NDI status, impacting product margins by 2-5% on average.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.